Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Intangibles (2022)

ImmunityBio (IBRX) has disclosed Change in Intangibles for 2 consecutive years, with $21.2 million as the latest value for Q1 2022.

  • On a quarterly basis, Change in Intangibles changed N/A to $21.2 million in Q1 2022 year-over-year; TTM through Dec 2022 was $21.2 million, a N/A change, with the full-year FY2022 number at $21.2 million, changed N/A from a year prior.
  • Change in Intangibles was $21.2 million for Q1 2022 at ImmunityBio, up from -$342000.0 in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $21.2 million in Q1 2022 to a low of $21.2 million in Q1 2022.